XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].The abstract, titled Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up, will be presented by the first author Johan Lund at a poster session on Friday, June 10, 16:30 - 17:45 CEST. The other authors